Bioextrax AB

Bioextrax AB

0.22
EUR
-0.01
(-4.41%)
-0.04EPS
10.51MMarket Cap
Nov 20Next Earn

Total Valuation

EUR

As of June 30, 2026, Bioextrax AB carries a market capitalization of 10.51M, placing it among publicly traded companies globally. Its enterprise value stands at 9.84M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap10.51M
Enterprise Value9.84M

Important Dates

Bioextrax AB's next confirmed earnings release is scheduled for November 20, 2026.

Earnings Date11/20/2026

Share Statistics

As of June 30, 2026, Bioextrax AB has 47.60M shares outstanding.

Shares Outstanding47.60M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 194.77, and the price-to-book ratio stands at 9.71.

PS Ratio194.77
PB Ratio9.71
P/TBV Ratio9.71
P/FCF Ratio-6.77
P/OCF Ratio-6.78

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 199.96 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 9.84M versus a market cap of 10.51M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales199.96

Financial Position

As of June 30, 2026, Bioextrax AB maintains a current ratio of 3.53, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

Current Ratio3.53
Quick Ratio2.95
Interest Coverage-17,630.00

Financial Efficiency

Over the twelve months ended June 30, 2026, Bioextrax AB posted a negative return on equity (ROE) of -124.01, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -107.51, reflecting losses generated across the asset base.

Return on Equity (ROE)-124.01
Return on Assets (ROA)-107.51

Stock Price Statistics

EUR

As of the close on November 17, 2026, Bioextrax AB's stock has gained approximately 12.84% over the past 52 weeks. The 50-day moving average sits at 0.21, while the 200-day moving average is 0.23.

52-Week Price Change12.84%
50-Day Moving Average0.21
200-Day Moving Average0.23

Income Statement

EUR

Over the twelve months ended June 30, 2026, Bioextrax AB generated 49,203.98 in revenue and converted that into -1.68M in net income, yielding earnings per share of -0.04. EBITDA reached -1.59M, while operating income came in at -1.69M.

Revenue49,203.98
Gross Profit-46,405.22
Operating Income-1.69M
Pretax Income-1.68M
Net Income-1.68M
EBITDA-1.59M
EBIT-1.69M
Earnings Per Share (EPS)-0.04

Balance Sheet

EUR

These figures are as of June 30, 2026. Total book value stands at 1.08M, with working capital of 571,759.29 providing operational flexibility.

Cash & Cash Equivalents667,278.21
Net Debt-667,278.21
Equity (Book Value)1.08M
Book Value Per Share0.02
Working Capital571,759.29

Cash Flow

EUR

Bioextrax AB produced -1.41M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -15,438.31 in capital expenditures, free cash flow totaled -1.43M - equivalent to -0.03 per share.

Operating Cash Flow-1.41M
Capital Expenditures-15,438.31
Free Cash Flow-1.43M
FCF Per Share-0.03

Margins

Over the twelve months ended June 30, 2026, Bioextrax AB posted a gross margin of -94.31, reflecting its pricing power and cost economics. The operating margin of -3,427.71 and net profit margin of -3,407.52 provide insight into operational efficiency.

Gross Margin-94.31
Operating Margin-3,427.71
Pretax Margin-3,407.52
Profit Margin-3,407.52
EBITDA Margin-3,234.86

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -14.78: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.81, meaning Bioextrax AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-10.81
FCF Yield-14.78

Stock Splits

Bioextrax AB's most recent stock split took place on October 9, 2026.

Last Split Date10/9/2026

Scores

As of June 30, 2026, Bioextrax AB has an Altman Z-Score of 25.09, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score25.09